» Articles » PMID: 14584041

Cripto-1 Overexpression Leads to Enhanced Invasiveness and Resistance to Anoikis in Human MCF-7 Breast Cancer Cells

Overview
Journal J Cell Physiol
Specialties Cell Biology
Physiology
Date 2003 Oct 30
PMID 14584041
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Cripto-1 (CR-1) is an epidermal growth factor (EGF)-CFC protein that has been shown to signal through nodal/Alk-4, PI3K/Akt, and/or ras/raf/MEK/MAPK pathways in mammalian cells, and that is frequently expressed in human primary breast carcinomas. In the present study, the human estrogen receptor positive, MCF-7 breast cancer cell line, that expresses low levels of endogenous CR-1, was transfected with a CR-1 expression vector. MCF-7 CR-1 cells expressed high levels of a 25 kDa recombinant CR-1 protein that was not detected in MCF-7 cells transfected with a control vector (MCF-7 neo). Overexpression of CR-1 did not induce an estrogen independent phenotype in MCF-7 cells. In fact, MCF-7 CR-1 cells showed a response to exogenous estrogens that was similar to MCF-7 neo cells, and failed to grow in immunosuppressed mice in absence of estrogen stimulation. However, MCF-7 CR-1 cells showed a rate of proliferation in serum free conditions, and an ability to form colonies in soft-agar that were higher as compared with MCF-7 neo cells. More importantly, overexpression of CR-1 enhanced the resistance to anoikis and the invasion ability of MCF-7 cells. MCF-7 CR-1 cells showed levels of activation of both Akt and Smad-2 that were significantly higher as compared with MCF-7 neo. These findings suggest that CR-1 overexpression might be associated with the progression towards a more aggressive phenotype in breast carcinoma, through the activation of both Akt and Smad-2 signalling pathways.

Citing Articles

Metabolic reprogramming and signaling adaptations in anoikis resistance: mechanisms and therapeutic targets.

He C, He J Mol Cell Biochem. 2025; .

PMID: 39821582 DOI: 10.1007/s11010-024-05199-3.


Anoikis-related subtype and prognosis analyses based on bioinformatics, and an expression verification of ANGPTL4 based on experiments of lung adenocarcinoma.

Shen X, Xie J, Liu S, Cai Y, Yuan S, Uehara Y J Thorac Dis. 2024; 16(8):5361-5378.

PMID: 39268091 PMC: 11388259. DOI: 10.21037/jtd-24-1123.


Identification and validation of an anoikis-related genes signature for prognostic implication in papillary thyroid cancer.

Zhao R, Lu Y, Wan Z, Qiao P, Yang L, Zhang Y Aging (Albany NY). 2024; 16(8):7405-7425.

PMID: 38663918 PMC: 11087102. DOI: 10.18632/aging.205766.


Understanding the role of Cripto-1 in cancer progression and therapeutic strategies.

Zeng Q, Gao Y, Zhou Y Clin Transl Oncol. 2022; 25(5):1135-1144.

PMID: 36456761 DOI: 10.1007/s12094-022-03023-2.


CRIPTO-1 Is Immunolocalized in the Syncytiotrophoblast of Ampullary Pregnancies.

Cabar F, Pereira P, Bandeira C, Bevilacqua E, Schultz R, Francisco R Biomed Res Int. 2022; 2022:4769790.

PMID: 35434129 PMC: 9012632. DOI: 10.1155/2022/4769790.